Jewel A Engle, MD | |
520 W Lincoln Ave Ste A, Ada, OH 45810-9466 | |
(419) 634-2015 | |
(419) 634-9420 |
Full Name | Jewel A Engle |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 520 W Lincoln Ave Ste A, Ada, Ohio |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1841521887 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 35068564 (Ohio) | Secondary |
207R00000X | Internal Medicine | 35068564 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jewel A Engle, MD 1001 Bellefontaine Ave, Lima, OH 45804-2800 Ph: (419) 998-4575 | Jewel A Engle, MD 520 W Lincoln Ave Ste A, Ada, OH 45810-9466 Ph: (419) 634-2015 |
News Archive
The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism.
Before they excise a tumor, surgeons need to determine exactly where the cancerous cells lie. Now, research published today in The Optical Society's (OSA) journal Optics Letters details a new technique that could give surgeons cheaper and more lightweight tools, such as goggles or hand-held devices, to identify tumors in real time in the operating room.
Sarcopenia is the aging-related loss of skeletal muscle mass and strength. Preventing sarcopenia is important for maintaining a high quality of life (QOL) in the aged population.
Biodel Inc. today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to LantusĀ® (insulin glargine).
SOLX, Inc. has announced U.S. Food and Drug (FDA) 510(k) clearance for the SOLX 790 to perform Titanium:Sapphire laser trabeculoplasty (TLT).
› Verified 2 days ago